Results 11 to 20 of about 13,346 (214)

Biology of GD2 ganglioside: implications for cancer immunotherapy [PDF]

Frontiers in Pharmacology, 2023
Part of the broader glycosphingolipid family, gangliosides are composed of a ceramide bound to a sialic acid-containing glycan chain, and locate at the plasma membrane.
Pierre Machy, Erwan Mortier, Stéphane Birklé   +2 more
doaj   +5 more sources

RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype

Biomedicines, 2020
The tumor-associated ganglioside GD2 represents an attractive target for cancer immunotherapy. GD2-positive tumors are more responsive to such targeted therapy, and new methods are needed for the screening of GD2 molecular tumor phenotypes. In this work,
Maxim Sorokin, Irina V Kholodenko, Daniel V Kalinovsky   +2 more
exaly   +4 more sources

Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma [PDF]

Biomolecules, 2022
Neuroblastoma is one of the few childhood cancers that carries a tumor-specific antigen in the form of a glycolipid antigen known as GD2. It has restricted expression in normal tissue, such as peripheral afferent nerves.
Godfrey Chi-Fung Chan, Chan Godfrey Chi-Fung   +1 more
exaly   +4 more sources

Expression of GD2 and GD3 in peripheral neuroblastic tumors

Indian Journal of Pathology and Microbiology
Purpose: The aim of this study was to explore the correlation between the expression of GD2 and GD3 and the histopathological types, risk groups, and chemotherapy in peripheral neuroblastic tumors (pNTs) and provide a theoretical basis for the selection ...
Xia Wei, Shaomei Li, Yizhen Wang
doaj   +4 more sources

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

Frontiers in Oncology, 2020
Gangliosides are carbohydrate-containing sphingolipids that are widely expressed in normal tissues, making most subtypes unsuitable as targets for cancer therapy. However, the disialoganglioside GD2 subtype has limited expression in normal tissues but is
Bassel Nazha, Taofeek K Owonikoko, Nazha Bassel   +2 more
exaly   +3 more sources

Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy

Journal of Immunology Research, 2017
Target selection is a key feature in cancer immunotherapy, a promising field in cancer research. In this respect, gangliosides, a broad family of structurally related glycolipids, were suggested as potential targets for cancer immunotherapy based on ...
Julien Fleurence, Sophie Fougeray, Meriem Bahri, Denis Cochonneau, Béatrice Clémenceau, François Paris, Andras Heczey, Stéphane Birklé   +7 more
doaj   +2 more sources

GD2 expression in breast cancer [PDF]

Oncotarget, 2017
Breast cancer (BC) is a heterogeneous disease, including different subtypes having diverse incidence, drug-sensitivity and survival rates. In particular, claudin-low and basal-like BC have mesenchymal features with a dismal prognosis. Disialoganglioside GD2 is a typical neuroectodermal antigen expressed in a variety of cancers.
ORSI, GIULIA, BARBOLINI, MONICA, Ficarra, G, TAZZIOLI, Giovanni, MANNI, Paola, PETRACHI, TIZIANA, MASTROLIA, ILENIA, Orvieto, E, SPANO, Maria Carlotta, PRAPA, MALVINA, KALECI, SHANIKO, D'AMICO, Roberto, Guarneri, V, Dieci, Mv, CASCINU, Stefano, Conte, P, PIACENTINI, Federico, DOMINICI, Massimo   +17 more
openaire   +5 more sources

DNA Vaccine Expressing the Mimotope of GD2 Ganglioside Induces Protective GD2 Cross-reactive Antibody Responses

Cancer Research, 2005
AbstractThe GD2 ganglioside expressed on neuroectodermally derived tumors, including neuroblastoma and melanoma, is weakly immunogenic in tumor-bearing patients and induces predominantly immunoglobulin (Ig)-M antibody responses in the immunized host. Here, we investigated whether interconversion of GD2 into a peptide mimetic form would induce GD2 cross-
Bolesta, Elizabeth, Kowalczyk, Aleksandra, Wierzbicki, Andrzej, Rotkiewicz, Piotr, Bambach, Barbara, Tsao, Chun-Yen, Horwacik, Irena, Kolinski, Andrzej, Rokita, Hanna, Brecher, Martin, Wang, Xinhui, Ferrone, Soldano, Kozbor, Danuta   +12 more
openaire   +4 more sources

Predicting GD2 expression across cancer types by the integration of pathway topology and transcriptome data [PDF]

Frontiers in Bioinformatics
BackgroundThe disialoganglioside GD2 is a key cancer therapy target due to its overexpression in several cancers and limited presence in normal tissues. However, experimental assessment is technically challenging and not routinely available. We developed
Arsenij Ustjanzew, Arsenij Ustjanzew, Arsenij Ustjanzew, Federico Marini, Federico Marini, Federico Marini, Saskia Wagner, Arthur Wingerter, Roger Sandhoff, Jörg Faber, Jörg Faber, Jörg Faber, Claudia Paret, Claudia Paret, Claudia Paret, Claudia Paret, Claudia Paret   +16 more
doaj   +2 more sources

GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma [PDF]

Clinical Cancer Research
Abstract Purpose: Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard of care, which includes surgery, radiation, and chemotherapy, is often responsible for cognitive, neurologic, and endocrine side effects ...
Roselia Ciccone, Concetta Quintarelli, Antonio Camera, Michele Pezzella, Simona Caruso, Simona Manni, Alessio Ottaviani, Marika Guercio, Francesca Del Bufalo, Maria Cecilia Quadraccia, Domenico Orlando, Stefano Di Cecca, Matilde Sinibaldi, Mariasole Aurigemma, Laura Iaffaldano, Andrea Sarcinelli, Maria Luisa D'Amore, Manuela Ceccarelli, Francesca Nazio, Veronica Marabitti, Ezio Giorda, Marco Pezzullo, Cristiano De Stefanis, Andrea Carai, Sabrina Rossi, Rita Alaggio, Giada Del Baldo, Marco Becilli, Angela Mastronuzzi, Biagio De Angelis, Franco Locatelli   +30 more
openaire   +7 more sources